EP3325005A4 - IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY - Google Patents

IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY Download PDF

Info

Publication number: EP3325005A4
Authority: EP; European Patent Office
Prior art keywords: immunotherapy; peptides; identification; major histocompatibility; histocompatibility complex
Prior art date: 2015-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16828158.2A

Other languages

German (de)

French (fr)

Other versions

EP3325005A1 (en

Inventor

Brian J. Czerniecki

Gary K. Koski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-17

Filing date

2016-03-04

Publication date

2019-03-27

2015-07-17 Priority claimed from PCT/US2015/041034 external-priority patent/WO2016011432A2/en

2016-03-04 Application filed by Individual filed Critical Individual

2018-05-30 Publication of EP3325005A1 publication Critical patent/EP3325005A1/en

2019-03-27 Publication of EP3325005A4 publication Critical patent/EP3325005A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)

EP16828158.2A 2015-07-17 2016-03-04 IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY Withdrawn EP3325005A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/US2015/041034 WO2016011432A2 (en)	2014-07-17	2015-07-17	Identification of immunogenic mhc class ii peptides for immune-based therapy
PCT/US2016/021042 WO2017014810A1 (en)	2015-07-17	2016-03-04	Identification of immunogenic mhc class ii peptides for immune-based therapy

Publications (2)

Publication Number	Publication Date
EP3325005A1 EP3325005A1 (en)	2018-05-30
EP3325005A4 true EP3325005A4 (en)	2019-03-27

Family

ID=57835029

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP16828158.2A Withdrawn EP3325005A4 (en)	2015-07-17	2016-03-04	IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY
EP16828163.2A Withdrawn EP3324990A4 (en)	2015-07-17	2016-04-07	IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP16828163.2A Withdrawn EP3324990A4 (en)	2015-07-17	2016-04-07	IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY

Country Status (5)

Country	Link
EP (2)	EP3325005A4 (en)
JP (3)	JP2018527286A (en)
CN (1)	CN107206045A (en)
CA (2)	CA2992925A1 (en)
WO (2)	WO2017014810A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3325005A4 (en) *	2015-07-17	2019-03-27	Brian J. Czerniecki	IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY
US20220370496A1 (en) *	2019-09-13	2022-11-24	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Her3 pulsed dc1 therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991008214A1 (en) *	1989-12-01	1991-06-13	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL145926A0 (en) *	2001-10-15	2002-07-25	Mor Research Applic Ltd	Peptide epitopes of mimotopes useful in immunomodulation
EP2258712A3 (en) *	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US7919098B2 (en) *	2002-03-26	2011-04-05	Zensun ( Shanghai ) Sci & Tech Co., Ltd.	ErbB-3 based methods and compositions for treating neoplasms
US7700299B2 (en) *	2005-08-12	2010-04-20	Hoffmann-La Roche Inc.	Method for predicting the response to a treatment
EP2049568A2 (en) *	2006-04-07	2009-04-22	Københavns Universitet	Erbb receptor-derived peptide fragments
ES2401484T3 (en) *	2006-06-15	2013-04-22	Novartis Ag	Vaccination regime against multi-dose flu-saving adjuvants
WO2010097186A1 (en) *	2009-02-24	2010-09-02	Roche Diagnostic Gmbh	Use of s-erbb-3 as a marker for cancer
JP2010200693A (en) *	2009-03-04	2010-09-16	Chiyoda Kako Kensetsu Kk	Culture device for producing dendritic cell vaccine and method for producing the dendritic cell
US8765383B2 (en) *	2009-04-07	2014-07-01	Genomic Health, Inc.	Methods of predicting cancer risk using gene expression in premalignant tissue
US8728456B2 (en) *	2009-07-31	2014-05-20	President And Fellows Of Harvard College	Programming of cells for tolerogenic therapies
RU2575978C2 (en) *	2010-03-15	2016-02-27	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	System and method of obtaining and storage of activated mature dendritic cells
JP2014516960A (en) *	2011-05-19	2014-07-17	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	Anti-human HER3 antibody and use thereof
KR102083957B1 (en) *	2011-12-05	2020-03-04	노파르티스 아게	Antibodies for epidermal growth factor receptor 3 (her3)
WO2015048793A2 (en) *	2013-09-30	2015-04-02	Daiichi Sankyo Co., Ltd.	Nucleic acid biomarker and use thereof
CN107106666A (en) *	2014-07-17	2017-08-29	布莱恩·J·赫尔尼奇	Identification of immunogenic MHC class II peptides for immune-based therapy
EP3325005A4 (en) *	2015-07-17	2019-03-27	Brian J. Czerniecki	IDENTIFICATION OF IMMUNOGENIC CLASS II PEPTIDES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX FOR IMMUNOTHERAPY

2016
- 2016-03-04 EP EP16828158.2A patent/EP3325005A4/en not_active Withdrawn
- 2016-03-04 JP JP2017502790A patent/JP2018527286A/en active Pending
- 2016-03-04 WO PCT/US2016/021042 patent/WO2017014810A1/en not_active Ceased
- 2016-03-04 CA CA2992925A patent/CA2992925A1/en not_active Abandoned
- 2016-04-07 WO PCT/US2016/026542 patent/WO2017014816A1/en not_active Ceased
- 2016-04-07 EP EP16828163.2A patent/EP3324990A4/en not_active Withdrawn
- 2016-04-07 JP JP2017502788A patent/JP2018521953A/en active Pending
- 2016-04-07 CA CA2992937A patent/CA2992937A1/en not_active Abandoned
- 2016-04-07 CN CN201680002764.1A patent/CN107206045A/en active Pending
2020
- 2020-10-14 JP JP2020173500A patent/JP2021043204A/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991008214A1 (en) *	1989-12-01	1991-06-13	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUNFA PENG ET AL: "Alterations in Barrett's-related adenocarcinomas: A proteomic approach", INTERNATIONAL JOURNAL OF CANCER, vol. 122, no. 6, 15 March 2008 (2008-03-15), pages 1303 - 1310, XP055178816, ISSN: 0020-7136, DOI: 10.1002/ijc.23258 *
See also references of WO2017014810A1 *

Also Published As

Publication number	Publication date
JP2021043204A (en)	2021-03-18
CN107206045A (en)	2017-09-26
EP3325005A1 (en)	2018-05-30
WO2017014816A1 (en)	2017-01-26
EP3324990A1 (en)	2018-05-30
CA2992937A1 (en)	2017-01-26
JP2018521953A (en)	2018-08-09
JP2018527286A (en)	2018-09-20
WO2017014810A1 (en)	2017-01-26
CA2992925A1 (en)	2017-01-26
EP3324990A4 (en)	2019-04-03

Legal Events

Date	Code	Title	Description
2018-04-27	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-05-30	17P	Request for examination filed	Effective date: 20170217
2018-05-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-05-30	AX	Request for extension of the european patent	Extension state: BA ME
2018-10-24	DAV	Request for validation of the european patent (deleted)
2018-10-24	DAX	Request for extension of the european patent (deleted)
2019-03-27	A4	Supplementary search report drawn up and despatched	Effective date: 20190221
2019-03-27	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/574 20060101AFI20190215BHEP Ipc: C07K 14/71 20060101ALI20190215BHEP Ipc: A61K 39/00 20060101ALI20190215BHEP Ipc: A61P 35/00 20060101ALI20190215BHEP Ipc: C12N 5/0783 20100101ALI20190215BHEP Ipc: C12N 5/0784 20100101ALI20190215BHEP
2020-02-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-03-18	18D	Application deemed to be withdrawn	Effective date: 20190924

Publication	Publication Date	Title
IL285403A (en)	2021-09-30	Polypeptides that remove an epitope for mhc of group i
EP3383418A4 (en)	2019-08-07	SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
EP3423044A4 (en)	2019-11-20	NANOVACCIN ACTIVANT STING FOR IMMUNOTHERAPY
IL263896A (en)	2019-01-31	T-cell preparations for immunotherapy
IL256922A (en)	2018-03-29	Pd-l1 (" programmed death-ligand 1" ) antibodies
EP3347026A4 (en)	2019-05-08	GENETIC MODIFICATION OF MACROPHAGES FOR IMMUNOTHERAPY
SG11202001368SA (en)	2020-03-30	Antigen-binding proteins tatrgeting shared antigens
EP3493827A4 (en)	2020-02-26	COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3373970A4 (en)	2019-07-10	NKG2D-IG FUSION PROTEIN FOR IMMUNOTHERAPY AGAINST CANCER
EP3645569A4 (en)	2021-03-24	IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
EP3390429A4 (en)	2019-07-17	MODIFIED CAPSIDIC PROTEINS FOR ENHANCED RELEASE OF PARVOVIRAL VECTORS
EP3402517A4 (en)	2020-01-15	IMMUNOTHERAPY OF CANCER
EP3458756A4 (en)	2020-01-15	FLANGE ADAPTER
HUE053239T2 (en)	2021-06-28	Humanized tau antibodies for the treatment of Alzheimer's disease
EP3419674A4 (en)	2019-11-13	IMMUNOTHERAPY TARGETING AMYLOIDOSIS
GB201511191D0 (en)	2015-08-12	T-cell epitopes for the immunotherapy of myeloma
EP3294165A4 (en)	2019-06-05	METHODS FOR IMPLANTATION OF BONE SCREW
DK2968485T3 (en)	2020-06-08	Peptide vaccine for the prevention and immunotherapy of Alzheimer's dementia
EP3379317A4 (en)	2019-03-20	IMAGING LENS
EP3291722A4 (en)	2019-03-27	IMPROVED LENS REFRACTOR
FR3017658B1 (en)	2019-04-12	EQUIPMENT DRIVE HOUSING FOR TURBOMACHINE
EP3519028A4 (en)	2020-05-27	HARNESS FOR HARNESS
EP3347098A4 (en)	2019-06-26	TARGETING MDA-5 ACTIVATION FOR CANCER IMMUNOTHERAPY
FR3056552B1 (en)	2018-08-31	EXTERNAL ANCHORING HARPOON FOR AIRCRAFT
EP3463420A4 (en)	2020-02-12	PEPTIDES FOR HAIR GROWTH